2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Review slidesets and expert analyses of key data from the 2020 Hematology Virtual Annual Meeting!

Nonmalignant Hematology

Capsule Summary Slidesets

Rilzabrutinib was well tolerated and associated with rapid, durable responses in heavily pretreated adults with immune thrombocytopenia.

Released: December 16, 2020

In patients with cGVHD after alloSCT and 2-5 prior lines of systemic therapy, belumosudil was well tolerated with response rates > 70% and a median DoR of 50 weeks.

Released: December 14, 2020

Early data suggest that the combination of itacitinib and calcineurin inhibitors as prophylaxis for GVHD was well tolerated in patients with hematologic malignancies undergoing stem cell transplantation.

Released: December 18, 2020

Baricitinib appears to be well tolerated and effective for patients with therapy-refractory severe chronic GVHD, demonstrating rapid and durable responses.

Released: December 17, 2020

HRQoL was sustained in the phase III BELIEVE study of luspatercept vs placebo in transfusion-dependent β-thalassemia.

Released: December 14, 2020

Among the first 10 study participants with ≥ 3 months of follow-up, CTX001 infusion achieved cessation of pRBC transfusions for TDT patients, and eliminated veno-occlusive events for severe SCD patients.

Released: December 16, 2020

Proof-of-concept phase I data for mitapivat, an oral, small molecule inhibitor of pyruvate kinase R, shows early evidence of efficacy and safety in patients with stable sickle cell disease.

Released: December 16, 2020

Data from REACH3 shows ruxolitinib significantly improves responses and symptoms at Week 24 in patients with cGVHD, and inadequate steroid response, when compared with BAT.

Released: December 9, 2020

Results from this phase III study of mycophenolate mofetil and a short course of corticosteroids vs corticosteroids alone as first-line treatment for patients with ITP shows the combination therapy to be safe and effective, reducing the rate of treatment failure by more than one half.

Released: December 11, 2020

Initial results from HOPE-B, the largest phase III study of gene therapy for hemophilia B to date, show etranacogene dezaparvovec yields clinically meaningful levels of factor IX activity within 6 months.

Released: December 10, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue